Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
GLMD Galmed Pharmaceuticals
Post Mkt Price
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Allen BaharaffDirector, President and Chief Executive Officer1.45M----57male05/02/2022
Dr. Liat HayardenyChief Scientist Officer400.61K----55male05/02/2022
Mr. Yohai StenzlerChief Accounting Officer333.49K----39male05/02/2022
Mr. Guy NehemyaChief Operating Officer and Data Protection Officer305.61K----37male05/02/2022
Mr. Doron CohenChief Financial Officer------55male05/02/2022
Dr. David Sidransky, M.D.Lead Independent Director------61male05/02/2022
Mr. Marshall A. HeinbergIndependent Director------65male05/02/2022
Mr. Shmuel NirIndependent Director------60male05/02/2022
Dr. Carol L. Brosgart, M.D.Independent Director------70female05/02/2022
Mr. Amir PoshinskiIndependent Director------61male05/02/2022
Company Overview More
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
CEO: Baharaff, Allen
Market: NASDAQ
Futu Hot List
SymbolLatest price%Chg


Back to the Top